GLP-1 medications have demonstrated cardiovascular benefits in clinical trials, including reduced risk of major cardiovascular events
For those not yet ready for standard titration, microdosing tirzepatide offers an alternative approach that starts even lower than 2.5 mg
Of those who quit due to side effects, 73% stopped during weeks 4 to 12
Clients choose us for our advanced techniques, bilingual communication, and dedication to enhancing natural beauty while promoting overall wellness
Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents)
(Source: Drug Discovery Trends, 2025) Tirzepatide Expanding Globally Japan Launch March 2026 On March 19, 2026, Eli Lilly and Mitsubishi Tanabe Pharma announced the availability of Zepbound in Japan a market with approximately 28 million people living with obesity